ASH25 Highlight – Extended Anticoagulation in VTE: Apixaban vs Rivaroxaban
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on LinkedIn:
”ASH25 Highlight – Extended Anticoagulation in VTE: Apixaban vs Rivaroxaban
Important new insights from a post-hoc analysis of the RENOVE randomized trial, evaluating safety during extended treatment (after ≥6 months of full-dose therapy) with apixaban or rivaroxaban by Prof Francis COUTURAUD
Key Findings (5-year outcomes):
• Clinically relevant bleeding (CRB): Similar between drugs at both full and reduced doses.
• Major bleeding: No significant differences across subgroups.
• Recurrent VTE: Low and comparable with both agents.
• Dose reduction: Consistently lowered CRB risk for both apixaban and rivaroxaban.
Takeaway:
Unlike early-treatment data where rivaroxaban shows higher bleeding risk, during extended therapy the safety profiles of apixaban and rivaroxaban appear equivalent. More trials are needed.”
Stay updated with Hemostasis Today.
-
Jul 26, 2026, 16:26Novi Yanti Sari: When MPNs Affect the Heart
-
Jul 26, 2026, 16:21Beyond Drugs: Can Museums Become a Medical Prescription?
-
Jul 26, 2026, 14:45Sarah Giorgia Grazia Giannone: An Exciting Chapter in Gene Therapy Research
-
Jul 26, 2026, 14:21Javed Anees: Cerebral Collateral Circulation in Acute Ischemic Stroke
-
Jul 26, 2026, 14:11André Picard։ Canadian Blood Supplies Drop Sharply, Urgent Donor Appeal Issued
-
Jul 26, 2026, 13:54Lorenzo Scalia: New Review Highlights Anticoagulant Strategies for Elderly Patients With Atrial Fibrillation
-
Jul 26, 2026, 13:32Ahmed Kotb: A Practical Guide to Von Willebrand Disease
-
Jul 26, 2026, 12:42Emmanuel J Favaloro: Celebrating Excellence in Scientific Peer Review
-
Jul 26, 2026, 12:20Advancing Sickle Cell Care Through Advocacy – American Society of Hematology